The predictive value of systemic immune inflammation index for pathological complete remission of triple negative breast cancer
10.3760/cma.j.cn115455-20240512-00393
- VernacularTitle:系统性免疫炎症指数对三阴性乳腺癌病理完全缓解的预测价值
- Author:
Huan JIE
1
;
Shirong ZHANG
1
;
Chunna GUO
1
;
Qiang LIU
1
;
Danping JIANG
1
;
Ruiwen LI
1
;
Songbai WANG
1
Author Information
1. 解放军联勤保障部队第926医院血液肿瘤科，开远 661606
- Publication Type:Journal Article
- Keywords:
Triple negative breast neoplasms;
Systemic immune inflammation index;
Neoadjuvant chemotherapy;
Prognosis
- From:
Chinese Journal of Postgraduates of Medicine
2025;48(10):945-948
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the predictive value of systemic immune inflammation index for the efficacyof neoadjuvant chemotherapy in triple negative breast cancer patients, and analyzed the relationship between pathological complete response (pCR) and prognosis.Methods:The clinical data of 146 patients with triple-negative breast cancer admitted to the 926th Hospital of the Joint Service Support Force of the PLA from January 2018 to December 2020 were retrospectively collected. All patients received neoadjuvant chemotherapy. After chemotherapy, the patients were divided into pCR group (62 cases) and non-pCR group (84 cases) according to whether the patients achieved pCR. Pathological characteristics and systemic immunoinflammatory index levels of the two groups were compared. Receiver operating characteristic (ROC) curve was used to analyze the predictive value of systemic immunoinflammatory index for pCR after neoadjuvant chemotherapy in patients with triple-negative breast cancer, and survival curves were drawn to compare the disease-free survival of the two groups.Results:The rate of axillary lymph node metastasis in pCR group was lower than that in non-pCR group: 37.10% (23/62) vs. 64.29% (54/84), there was statistical difference ( χ2 = 10.58, P<0.01). There were no significant differences in TNM stage, Ki-67 level and histological grade between the two groups ( P>0.05). Compared with the non -pCR group, the systemic immune inflammation index in the pCR group was significantly reduced: 617.42 ± 166.40 vs. 853.67 ± 202.41, P<0.01. Systemic immune inflammation index was valuable in predicting non-pCR of triple negative breast cancer patients after neoadjuvant chemotherapy, and the area under the curve was 0.807 (95% CI: 0.738 - 0.875, P<0.01). Compared with the non-pCR group, the disease-free survival of patients in the pCR group was significantly prolonged ( P = 0.033). Conclusions:Systemic immune inflammation index was related to the efficacy of neoadjuvant chemotherapy in triple negative breast cancer patients, and can be used as a biological indicator to predict the efficacy of neoadjuvant chemotherapy in triple negative breast cancer.
